Sign in
Taking peopleNo phase

Registry study of lymphoma in people living with HIV

Collects data on treatment and outcomes in adults with HIV-related lymphoma.

Key facts

Who runs it
Rotkreuzklinikum München gGmbH
Where
Cardiff, United KingdomSee the siteAlso in 3 other countries, 5 sites
Trial code
Registry title
A Registry Study on HIV-related Lymphoma
Status
Recruiting
People taking part
300 people, planned
Started
25 Aug 2021
Expected to end
31 Aug 2029
Type of study
Observational
Record updated
6 April 2023

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with HIV who have been diagnosed with Hodgkin or non-Hodgkin lymphoma since 01.01.2010. It collects data on their disease, treatment and outcome.

Age
18 years or older
Sex
Women and men can join.
Disease stage
Hodgkin lymphoma or non-Hodgkin lymphoma, proven by tissue or cell tests.
Biomarker or test result
HIV infection at the time the lymphoma was diagnosed.

Main reasons for not taking part

  • HIV was diagnosed more than 3 months after the lymphoma diagnosis
  • For the prospective part: cannot or will not attend follow-up

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Histology or cytology proven non-Hodgkin lymphoma or Hodgkin lymphoma
  • HIV-infection at time of lymphoma diagnosis
  • Lymphoma diagnosis since 01.01.2010
  • Adult patients ≥ 18 years
  • Written informed consent

Who cannot take part

  • HIV-diagnosis > 3 months after the diagnosis of malignant lymphoma
  • Non-Compliance or lack of opportunity for follow-up (for the prospective part of the study)

Where in United Kingdom

Also in 3 other countries, 5 sites

  • University Hospital of WalesCardiff, United KingdomContact: Emily Hopkins, MDNot yet recruiting

About the trial

What the trial wants to find out

Retrospective und prospective registry on HIV-associated lymphoma. Data on characteristics, type and toxicity of treatment and outcome of patients with HIV-lymphoma will be collected.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Characteristics, Treatment and Outcomes of HIV-infected Patients With Malignant Lymphoma: A Registry Study of the European Hematology Association (EHA) Lymphoma Group
Plain-language title
Registry study of lymphoma in people living with HIVGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
6 April 2023